Schrödinger launches Tectora Therapeutics with $55 million Series A to target immunology and inflammation

Schrödinger announced the formation of Tectora Therapeutics, a new biotech focused on immune‑mediated diseases, backed by a $55 million Series A financing round.

As part of the launch, Schrödinger transferred two early‑stage small‑molecule programs to Tectora, gaining an equity stake and the right to future milestones and royalties.

Tectora will work with Schrödinger’s drug‑discovery team and use its physics‑based computational chemistry platform to advance the candidates toward oral treatments for immunology and inflammation, operating in stealth mode.

The move reflects Schrödinger’s strategy of expanding its discovery collaborations beyond its software business.